跳转至内容
Merck
CN

SML3955

Cdk5i-FT trifluoroacetate

≥95% (HPLC)

别名:

Ahx = 6-aminohexanoate) trifluoroacetate, FITC-Ahx-ARAFGIPVRCYS-TAT trifluoroacetate, FITC-Ahx-ARAFGIPVRCYS-YGRKKRRQRRR (FITC = fluorescein isothiocyanate, FITC-Ahx-Cdk5i-TAT trifluoroacetate

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

经验公式(希尔记法):
C151H232N52O34S2 · xC2HF3O2
分子量:
3383.92 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.21
Assay:
≥95% (HPLC)
Form:
(Powder or Lyophilized powder or film)
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Segment

assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

storage condition

desiccated

color

white to beige

storage temp.

-10 to -25°C

Biochem/physiol Actions

Brain-penetrant and selective cyclin-dependent kinase Cdk5/p25 complex inhibitor that improves neurodegenerative phenotypes in cultures and in vivo.

Cdk5i-FT is a brain-penetrant and selective cyclin-dependent kinase Cdk5/p25 complex inhibitor that is composed of Cdk5i, a human Cdk5-derived 12-aa p25-binding sequence (Kd = 220 nM) followed by a C-terminal TAT sequence and FITC-conjugated via a 6-aminohexanoate linker at its N-terminus. Cdk5i-FT inhibits Cdk5/p25 kinase activity in vitro by disrupting Cdk5-p25 interaction and protects neurons from Cdk5 hyperactivity-induced death in cultures (10 nM). Cdk5i-FT exhibits therapeutic efficacy in murine neurodegeneration models in vivo (20 mg/kg q.a.d. i.p.), using CK-p25 mice (with inducible p25 overexpress in forebrain neurons) and Tau P301S mice (with Cdk5-mediated Tau S301 hyperphosphorylation).

Disclaimer

Hygroscopic


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库